Literature DB >> 32181801

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Sattva S Neelapu1, Caron A Jacobson2, Olalekan O Oluwole3, Javier Munoz4, Abhinav Deol5, David B Miklos6, Nancy L Bartlett7,8, Ira Braunschweig9, Yizhou Jiang10, Jenny J Kim10, Lianqing Zheng10, John M Rossi10, Frederick L Locke11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32181801      PMCID： PMC7273828          DOI： 10.1182/blood.2019004162

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

Review 1.  Difficulties in decision making regarding chemotherapy for older cancer patients: A census of cancer physicians.

Authors:  Doreen Wan-Chow-Wah; Johanne Monette; Michèle Monette; Nadia Sourial; Frédérique Retornaz; Gerald Batist; Martine T E Puts; Howard Bergman
Journal:  Crit Rev Oncol Hematol       Date:  2010-03-23       Impact factor: 6.312

2.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Authors:  Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2018-12-02       Impact factor: 41.316

4.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

5.  Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.

Authors: 
Journal:  Blood       Date:  2018-02-01       Impact factor: 22.113

6.  Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.

Authors:  Lova Sun; Shuli Li; Areej El-Jawahri; Philippe Armand; Bimalangshu R Dey; David C Fisher; Eric D Jacobsen; Caron A Jacobson; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Yi-Bin Chen; Zachariah DeFilipp
Journal:  Oncologist       Date:  2017-12-28

7.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.

Authors:  Frederick L Locke; Sattva S Neelapu; Nancy L Bartlett; Tanya Siddiqi; Julio C Chavez; Chitra M Hosing; Armin Ghobadi; Lihua E Budde; Adrian Bot; John M Rossi; Yizhou Jiang; Allen X Xue; Meg Elias; Jeff Aycock; Jeff Wiezorek; William Y Go
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454
  8 in total
  19 in total

Review 1.  Sequencing of Novel Therapies for Mantle Cell Lymphoma.

Authors:  Jason T Romancik; Jonathon B Cohen
Journal:  Curr Treat Options Oncol       Date:  2021-11-23

2.  Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.

Authors:  Jiannan Chen; Jianhua Hu; Lili Gu; Feng Ji; Fan Zhang; Miaomiao Zhang; Jun Li; Zhengliang Chen; Longwei Jiang; Yan Zhang; Ruifang Shi; Lihua Ma; Shaochang Jia; Ying Zhang; Qi Zhang; Junqing Liang; Shunyu Yao; Zhigang Hu; Zhigang Guo
Journal:  Cancer Immunol Immunother       Date:  2022-08-04       Impact factor: 6.630

Review 3.  Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Authors:  Miguel-Angel Perales; Larry D Anderson; Tania Jain; Saad S Kenderian; Olalekan O Oluwole; Gunjan L Shah; Jakub Svoboda; Mehdi Hamadani
Journal:  Transplant Cell Ther       Date:  2022-06-26

4.  An overview of multiplexed analyses of CAR T-cell therapies: insights and potential.

Authors:  Brittany Paige DePriest; Noah Vieira; Alan Bidgoli; Sophie Paczesny
Journal:  Expert Rev Proteomics       Date:  2021-10-17       Impact factor: 4.250

Review 5.  Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Authors:  Anupama Doraiswamy; Mansi R Shah; Rajat Bannerji
Journal:  Curr Hematol Malig Rep       Date:  2021-02-22       Impact factor: 3.952

Review 6.  Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies.

Authors:  Mark B Leick; Marcela V Maus; Matthew J Frigault
Journal:  Mol Ther       Date:  2020-10-31       Impact factor: 11.454

Review 7.  How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.

Authors:  Jennifer M Logue; Julio C Chavez
Journal:  Curr Treat Options Oncol       Date:  2021-10-26

Review 8.  Advances in Management for Older Adults With Hematologic Malignancies.

Authors:  Ashley E Rosko; Raul Cordoba; Gregory Abel; Andrew Artz; Kah Poh Loh; Heidi D Klepin
Journal:  J Clin Oncol       Date:  2021-05-27       Impact factor: 50.717

9.  Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma.

Authors:  Raphael E Steiner; Jose Banchs; Efstratios Koutroumpakis; Melody Becnel; Cristina Gutierrez; Paolo Strati; Chelsea C Pinnix; Lei Feng; Gabriela Rondon; Catherine Claussen; Nicolas Palaskas; Kaveh Karimzad; Sairah Ahmed; Sattva S Neelapu; Elizabeth Shpall; Michael Wang; Francisco Vega; Jason Westin; Loretta J Nastoupil; Anita Deswal
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

Review 10.  Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.

Authors:  Mengyang Di; Scott F Huntington; Adam J Olszewski
Journal:  Oncologist       Date:  2020-12-09       Impact factor: 5.837
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.